Abstract
Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995–2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. Results: 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR = 2.5 [1.1, 2.5]); (2) ≥3 versus 1 line of chemotherapy for NHL (HR = 1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005–2010 versus 1995–1999 (HR = 2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5–10 times the background rate. In contrast, relative risks were 10–50 for AML and approximately 100 for MDS in the autotransplant cohort. Conclusions: There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 130-136 |
| Number of pages | 7 |
| Journal | Leukemia Research |
| Volume | 74 |
| DOIs | |
| State | Published - Nov 2018 |
Keywords
- AML
- Autotransplant
- CIBMTR
- MDS
- New cancers
- SEER
- Therapy-related
ASJC Scopus subject areas
- Hematology
- Oncology
- Cancer Research
Access to Document
Other files and links
Fingerprint Dive into the research topics of 'Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma'. Together they form a unique fingerprint.
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. / Radivoyevitch, Tomas; Dean, Robert M.; Shaw, Bronwen E.; Brazauskas, Ruta; Tecca, Heather R.; Molenaar, Remco J.; Battiwalla, Minoo; Savani, Bipin N.; Flowers, Mary E.D.; Cooke, Kenneth R.; Hamilton, Betty K.; Kalaycio, Matt; Maciejewski, Jaroslaw P.; Ahmed, Ibrahim; Akpek, Görgün; Bajel, Ashish; Buchbinder, David; Cahn, Jean Yves; D'Souza, Anita; Daly, Andrew; DeFilipp, Zachariah; Ganguly, Siddhartha; Hamadani, Mehdi; Hayashi, Robert J.; Hematti, Peiman; Inamoto, Yoshihiro; Khera, Nandita; Kindwall-Keller, Tamila; Landau, Heather; Lazarus, Hillard; Majhail, Navneet S.; Marks, David I.; Olsson, Richard F.; Seo, Sachiko; Steinberg, Amir; William, Basem M.; Wirk, Baldeep; Yared, Jean A.; Aljurf, Mahmoud; Abidi, Muneer H.; Allewelt, Heather; Beitinjaneh, Amer; Cook, Rachel; Cornell, Robert F.; Fay, Joseph W.; Hale, Gregory; Chakrabarty, Jennifer Holter; Jodele, Sonata; Kasow, Kimberly A.; Mahindra, Anuj; Malone, Adriana K.; Popat, Uday; Rizzo, J. Douglas; Schouten, Harry C.; Warwick, Anne B.; Wood, William A.; Sekeres, Mikkael A.; Litzow, Mark R.; Gale, Robert P.; Hashmi, Shahrukh K.
In: Leukemia Research, Vol. 74, 11.2018, p. 130-136.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma
AU - Radivoyevitch, Tomas
AU - Dean, Robert M.
AU - Shaw, Bronwen E.
AU - Brazauskas, Ruta
AU - Tecca, Heather R.
AU - Molenaar, Remco J.
AU - Battiwalla, Minoo
AU - Savani, Bipin N.
AU - Flowers, Mary E.D.
AU - Cooke, Kenneth R.
AU - Hamilton, Betty K.
AU - Kalaycio, Matt
AU - Maciejewski, Jaroslaw P.
AU - Ahmed, Ibrahim
AU - Akpek, Görgün
AU - Bajel, Ashish
AU - Buchbinder, David
AU - Cahn, Jean Yves
AU - D'Souza, Anita
AU - Daly, Andrew
AU - DeFilipp, Zachariah
AU - Ganguly, Siddhartha
AU - Hamadani, Mehdi
AU - Hayashi, Robert J.
AU - Hematti, Peiman
AU - Inamoto, Yoshihiro
AU - Khera, Nandita
AU - Kindwall-Keller, Tamila
AU - Landau, Heather
AU - Lazarus, Hillard
AU - Majhail, Navneet S.
AU - Marks, David I.
AU - Olsson, Richard F.
AU - Seo, Sachiko
AU - Steinberg, Amir
AU - William, Basem M.
AU - Wirk, Baldeep
AU - Yared, Jean A.
AU - Aljurf, Mahmoud
AU - Abidi, Muneer H.
AU - Allewelt, Heather
AU - Beitinjaneh, Amer
AU - Cook, Rachel
AU - Cornell, Robert F.
AU - Fay, Joseph W.
AU - Hale, Gregory
AU - Chakrabarty, Jennifer Holter
AU - Jodele, Sonata
AU - Kasow, Kimberly A.
AU - Mahindra, Anuj
AU - Malone, Adriana K.
AU - Popat, Uday
AU - Rizzo, J. Douglas
AU - Schouten, Harry C.
AU - Warwick, Anne B.
AU - Wood, William A.
AU - Sekeres, Mikkael A.
AU - Litzow, Mark R.
AU - Gale, Robert P.
AU - Hashmi, Shahrukh K.
N1 - Funding Information: The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID); a Grant/Cooperative Agreement 4U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-17-1?2388 and N0014-17-1?2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. ? Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick's Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. TR is supported by the National Aeronautics and Space Administration (NNJ13ZSA001N). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. *Corporate Members Funding Information: The CIBMTR is supported primarily by Public Health Service Grant/Cooperative Agreement 5U24CA076518 from the National Cancer Institute (NCI) , the National Heart , Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases (NIAID) ; a Grant/Cooperative Agreement 4U10HL069294 from NHLBI and NCI; a contract HHSH250201200016C with Health Resources and Services Administration (HRSA/DHHS); two Grants N00014-17-1–2388 and N0014-17-1–2850 from the Office of Naval Research; and grants from *Actinium Pharmaceuticals, Inc.; *Amgen, Inc.; *Amneal Biosciences; *Angiocrine Bioscience, Inc.; Anonymous donation to the Medical College of Wisconsin; Astellas Pharma US; Atara Biotherapeutics, Inc.; Be the Match Foundation; *bluebird bio, Inc.; *Bristol Myers Squibb Oncology; *Celgene Corporation; Cerus Corporation; *Chimerix, Inc.; Fred Hutchinson Cancer Research Center; Gamida Cell Ltd.; Gilead Sciences, Inc.; HistoGenetics, Inc.; Immucor; *Incyte Corporation; Janssen Scientific Affairs, LLC; *Jazz Pharmaceuticals, Inc.; Juno Therapeutics; Karyopharm Therapeutics, Inc.; Kite Pharma, Inc.; Medac, GmbH; MedImmune; The Medical College of Wisconsin; *Mediware; *Merck & Co, Inc.; *Mesoblast; MesoScale Diagnostics, Inc.; Millennium, the Takeda Oncology Co.; *Miltenyi Biotec, Inc.; National Marrow Donor Program; *Neovii Biotech NA, Inc.; Novartis Pharmaceuticals Corporation; Otsuka Pharmaceutical Co, Ltd. – Japan; PCORI; *Pfizer, Inc; *Pharmacyclics, LLC; PIRCHE AG; *Sanofi Genzyme; *Seattle Genetics; Shire; Spectrum Pharmaceuticals, Inc.; St. Baldrick’s Foundation; *Sunesis Pharmaceuticals, Inc.; Swedish Orphan Biovitrum, Inc.; Takeda Oncology; Telomere Diagnostics, Inc.; and University of Minnesota. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense, Health Resources and Services Administration (HRSA) or any other agency of the U.S. Government. TR is supported by the National Aeronautics and Space Administration (NNJ13ZSA001N). RPG acknowledges support from the National Institute of Health Research (NIHR) Biomedical Research Centre funding scheme. *Corporate Members Publisher Copyright: © 2018
PY - 2018/11
Y1 - 2018/11
N2 - Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995–2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. Results: 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR = 2.5 [1.1, 2.5]); (2) ≥3 versus 1 line of chemotherapy for NHL (HR = 1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005–2010 versus 1995–1999 (HR = 2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5–10 times the background rate. In contrast, relative risks were 10–50 for AML and approximately 100 for MDS in the autotransplant cohort. Conclusions: There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.
AB - Background: Exposures to DNA-damaging drugs and ionizing radiations increase risks of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). Methods: 9028 recipients of hematopoietic cell autotransplants (1995–2010) for Hodgkin lymphoma (HL; n = 916), non-Hodgkin lymphoma (NHL; n = 3546) and plasma cell myeloma (PCM; n = 4566), reported to the CIBMTR, were analyzed for risk of subsequent AML or MDS. Results: 335 MDS/AML cases were diagnosed posttransplant (3.7%). Variables associated with an increased risk for AML or MDS in multivariate analyses were: (1) conditioning with total body radiation versus chemotherapy alone for HL (HR = 4.0; 95% confidence interval [1.4, 11.6]) and NHL (HR = 2.5 [1.1, 2.5]); (2) ≥3 versus 1 line of chemotherapy for NHL (HR = 1.9 [1.3, 2.8]); and (3) subjects with NHL transplanted in 2005–2010 versus 1995–1999 (HR = 2.1 [1.5, 3.1]). Using Surveillance, Epidemiology and End Results (SEER) data, we found risks for AML/MDS in HL, NHL and PCM to be 5–10 times the background rate. In contrast, relative risks were 10–50 for AML and approximately 100 for MDS in the autotransplant cohort. Conclusions: There are substantial risks of AML and MDS after autotransplants for HL, NHL and PCM.
KW - AML
KW - Autotransplant
KW - CIBMTR
KW - MDS
KW - New cancers
KW - SEER
KW - Therapy-related
UR - http://www.scopus.com/inward/record.url?scp=85050340275&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85050340275&partnerID=8YFLogxK
U2 - 10.1016/j.leukres.2018.07.016
DO - 10.1016/j.leukres.2018.07.016
M3 - Article
C2 - 30055822
AN - SCOPUS:85050340275
VL - 74
SP - 130
EP - 136
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
ER -